Britta Siegmund

Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

1 University Hospital CHU of Liège, Liège, Belgium, Liège, Belgium; 2 University of Calgary, Calgary, Alberta, Canada; 3 Barts Health NHS Trust, London, United Kingdom; 4 NGERE, Faculty o...

Su Chen ;

W. Rachel Duan ;

Alessandro Armuzzi ;

Luc Biedermann ;

Stefan Schreiber ;

Edouard Louis ;

Remo Panaccione ;

Gareth Parkes ;

Laurent Pevrin-Biroulet ;

Marc Ferrante ;

Britta Siegmund ;

Phillip Levine ;

Gil Y. Melmed , MD;

Jasmina Kalabic ;

Ken Takeuchi , MD, PhD;

Ezequiel Neimark ;

Edward V. Loftus Jr., MD;

Kori Wallace ;

01/11/2024

Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial

1 Nancy University Hospital, Vandoeuvre-les-Nancy, France; 2 GI Alliance, United States; 3 Icahn School of Medicine at Mount Sinai, New York, United States; 4 UNIMI, Department of Pathoph...

Xiu Huang ;

Sofie Berg ;

Lei Shu ;

Kristina Kligys ;

Remo Panaccione ;

Marc Ferrante ;

Britta Siegmund ;

Jean-Frederic Colombel ;

Ezequiel Neimark ;

Geert D'Haens ;

Kori Wallace ;

Marla C. Dubinsky , MD;